Biopharmaceutical CEO discusses promising Phase 3 trial results of a novel antibiotic for Clostridioides difficile Infections with potential market impact exceeding $1B |David P Luci , CEO, Acurx Pharmaceuticals Inc. 00:10:00
In an interview , David Luci, the President/CEO of a clinical-stage biopharmaceutical company, provides updates on their FDA Phase 3 trial for a novel antibiotic, Ibezapolstat, targeting Clostridioides difficile Infections (CDI), highlighting its impressive success rate in Phase 2 trials and potential market impact exceeding $1 billion.
